Healthplus.ai
Healthplus.ai is a company focused on enabling proactive surgical care through personalized complication predictions and management. Their AI-powered EHR-integrated decision support system, PERISCOPE®, uses existing data and a powerful AI engine to identify patients at high, medium, or low risk of infection post-surgery. The goal is to reduce physician and nurse workload, safely discharge patients, lower readmissions, speed up recovery, and decrease costs. PERISCOPE® is recalibrated and validated to adapt to specific hospital data and workflows, offering benefits to patients, healthcare providers, payers, and hospitals. They have received recognition such as the CES 2024 Innovation Award for digital health and ISO 13485 and ISO 27001 certifications.
Healthplus.ai
Healthplus.ai is a company focused on enabling proactive surgical care through personalized complication predictions and management. Their AI-powered EHR-integrated decision support system, PERISCOPE®, uses existing data and a powerful AI engine to identify patients at high, medium, or low risk of infection post-surgery. The goal is to reduce physician and nurse workload, safely discharge patients, lower readmissions, speed up recovery, and decrease costs. PERISCOPE® is recalibrated and validated to adapt to specific hospital data and workflows, offering benefits to patients, healthcare providers, payers, and hospitals. They have received recognition such as the CES 2024 Innovation Award for digital health and ISO 13485 and ISO 27001 certifications.
TL;DR
Product: PERISCOPE® — EHR-integrated AI SaMD for predicting 7- and 30-day postoperative bacterial infection risk
HQ: Amsterdam, the Netherlands
Founding year: 2017
Employees: 14
Funding (total): USD 2,360,000
Recent funding: Seed round announced Aug 1, 2024; lead investor listed as Cedars‑Sinai Accelerator
Company Overview
Problem Domain
Postoperative infection prediction and perioperative patient management
Founded
2017
Industry
Digital health / Healthtech
Funding Track Record
Seed round announced Aug 1, 2024
Pre-seed partnership with LUMO labs reported May 17, 2022
Received grants from the European Commission / EASME and other recorded awards
Investor Signal
“Cedars‑Sinai Accelerator and LUMO labs are among reported investors”